Vir Biotechnology, Alnylam Identify VIR-2703 Candidate For Treatment Of COVID-19

Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that they have selected a development candidate (DC) for VIR-2703 (ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 (COVID-19) genome.

from RTT - Biotech https://ift.tt/2KZSrqW
via IFTTT